Study S001175

A Phase 1/2A Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT06937203
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 150
Start: 2025-05-09
Primary completion: 2027-02
Lead sponsor: Arrowhead Pharmaceuticals
Conditions: Obesity; Diabetes Mellitus, Type 2
Interventions: DRUG:ARO-ALK7; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Number of Participants with Treatment-Emergent Adverse Events (TEAEs) [Up to Day 253 End of Study (EOS)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.